U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H108N6O19P.Na
Molecular Weight 1259.4812
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIFAMURTIDE ANHYDROUS

SMILES

[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC

InChI

InChIKey=LRSAONQAUPMYDK-XNLRRNFISA-M
InChI=1S/C59H109N6O19P.Na/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68;/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79);/q;+1/p-1/t43-,44-,45+,47+,48+,49-,50+,54+,55+;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6965228 | https://www.ncbi.nlm.nih.gov/pubmed/2302725 | https://www.ncbi.nlm.nih.gov/pubmed/10851426

Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine; trade name Mepact) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. After intravenous administration, mifamurtide is selectively phagocytosed by monocytes and macrophages. Cytosolic Mifamurtide specifically interacts with nucleotide-binding oligomerization domain 2 (NOD2) receptor that induces nuclear factor (NF)-kB activation and is implicated in innate immune defense. Activation of monocyte-mediated tumoricidal function was observed following in vivo treatment with mifamurtide in phase I/II clinical trials. Intravenous administration of mifamurtide inhibited tumor growth and increased survival in rodent models of lung and liver metastasis. In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high-grade, non-metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection; it is administered by intravenous infusion in conjunction with postoperative multiagent chemotherapy. In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma.

Originator

Curator's Comment: Mifamurtide [N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanyl-2- (l',2'-dipalmitoyl-sn-glycero-3'-phosphoryl)-ethylamide] was the gift of Ciba-Geigy Ltd, Basel, Switzerland.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Mepact

Approved Use

Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.
PubMed

PubMed

TitleDatePubMed
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
2017 Aug
Patents

Patents

Sample Use Guides

2 mg/m2 infused intravenously over 1 hour twice weekly (at least 3 days apart) for 12 weeks, followed by 2 mg/m2 once weekly for an additional 24 weeks, for a total of 48 infusions in 36 weeks
Route of Administration: Intravenous
In Vitro Use Guide
Monocytes (10^5) of 14 healthy donors and 24 cancer patients were used for activity evaluation. Monocytes were incubated for 24 h in medium with or without 500 nmol/ml liposome-encapsulated Mifamurtide. Then, the monocytes were washed and incubated with 10^4 labeled A375 melanoma cells. The assays were terminated 72 h later. The percentage cytotoxicities of untreated monocytes and tumor cells were compared.
Name Type Language
MIFAMURTIDE ANHYDROUS
Common Name English
SODIUM (5S,10R,13S,16R)-16-(((3R,4R,5S,6R)-3-ACETAMIDO-2,5-DIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-4-YL)OXY)-10-CARBAMOYL-5,13-DIMETHYL-4,7,12,15-TETRAOXO-3,6,11,14-TETRAAZAHEPTADECYL ((R)-2,3-BIS(PALMITOYLOXY)PROPYL) PHOSPHATE
Systematic Name English
MIFAMURTIDE SODIUM
Common Name English
MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE S
Common Name English
MEPACT SODIUM SALT
MI  
Common Name English
CGP-19835A
Code English
MIFAMURTIDE SODIUM SALT [MI]
Common Name English
MIFAMURTIDE SODIUM SALT
Common Name English
SODIUM (R)-2,3-BIS(PALMITOYLOXY)PROPYL ((4R,5R,7R,10S,13R,18S)-13-CARBAMOYL-4-FORMYL-7,10,18-TRIMETHYL-2,8,11,16,19-PENTAOXO-5-((1R,2R)-1,2,3-TRIHYDROXYPROPYL)-6-OXA-3,9,12,17,20-PENTAAZADOCOSAN-22-YL) PHOSPHATE
Systematic Name English
JUNOVAN
Brand Name English
MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE SODIUM SALT
Common Name English
Code System Code Type Description
PUBCHEM
76972714
Created by admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
PRIMARY
MERCK INDEX
m7535
Created by admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
PRIMARY
SMS_ID
100000183845
Created by admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
PRIMARY
CAS
90825-43-7
Created by admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
PRIMARY
FDA UNII
21G81IKJ8L
Created by admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
PRIMARY